We harness the power of molecular microbiology and bioinformatics to develop diagnostic solutions that will optimize the treatment of life-threatening, drug resistant infections. We seek to dramatically transform patient care by using precision medicine to guide antibiotic therapy selection and help improve antibiotic stewardship.
Headquartered in Rockville, Maryland, OpGen is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. OpGen, along with its subsidiaries, Curetis and Ares Genetics, develop and commercialize molecular microbiology solutions to help guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes.
Our innovative approaches to infectious disease diagnostics consist of highly multiplexed syndromic molecular panels, and next-generation sequencing combined with smart bioinformatics and artificial intelligence to address the global threat of antimicrobial resistance (AMR).
By integrating these capabilities, we provide unique rapid molecular diagnostic products and services that help to dramatically transform patient care by using precision medicine to guide antibiotic therapy selection and optimize the treatment of life-threatening drug-resistant infections, improve antibiotic stewardship, and decrease the spread of multidrug-resistant microorganisms (MDROs).
Unyvero System and multiplex syndromic panels, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb using next-generation sequencing (NGS) technology and AI-powered bioinformatics solutions for antibiotic response prediction.
Together we improve patient care and fight AMR through cutting edge molecular microbiology.
OpGen and its group companies are striving to innovate molecular microbiology.